Endo Says FTC Is Overreacting To Latest Impax Opioid Deal
Endo Pharmaceuticals is pushing for the dismissal of a Federal Trade Commission antitrust suit alleging it entered a second "pay-for-delay" agreement with Impax Laboratories over Endo's Opana ER painkiller, arguing the...To view the full article, register now.
Already a subscriber? Click here to view full article